In June, 2026, Mingowood Pharmacal presented its Intercalyx™ technology platform for acidic cannabinoid stabilization at ICRS Symposium, 2026. Managing Partner Dr. Benjamin Cameransi met with cannabis researchers and potential licensing partners.
On August 12, 2025, Mingowood Pharmacal announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 12,377,109 for its novel formulation technology. The patent, "Formulation and Noncovalent Stabilization of Olivetolic Acid Derivatives," covers a new method for effectively stabilizing acidic cannabinoids such as CBGA, CBDA, and THCA.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.